Download PDF
Adipositas - Ursachen, Folgeerkrankungen, Therapie 2009; 03(02): 71-76
DOI: 10.1055/s-0037-1618665
Adipositas und Pharmakotherapie
Schattauer GmbH

Metabolische Risiken in der Behandlung der Schizophrenie

Metabolic risks in the treatment of schizophrenia
G. Kotrotsios
1   LVR-Klinikum Düsseldorf, Kliniken der Heinrich-Heine-Universität Düsseldorf
,
J. Cordes
1   LVR-Klinikum Düsseldorf, Kliniken der Heinrich-Heine-Universität Düsseldorf
,
E. M. Canales
1   LVR-Klinikum Düsseldorf, Kliniken der Heinrich-Heine-Universität Düsseldorf
,
K. G. Kahl
2   Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Medizinische Hochschule Hannover
› Author Affiliations
Further Information

Publication History

Publication Date:
21 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Bei schizophrenen Patienten besteht bereits unabhängig von der Medikation eine erhöhte Prävalenz des metabolischen Syndroms. Darüber hinaus komplizieren metabolische Nebenwirkungen die Pharmakotherapie der Schizophrenie. Aufgrund zunehmender Polypharmazie summieren sich metabolische Begleiteffekte der verschiedenen Psychopharmaka. Daher sind folgende Aspekte in der Therapie von Patienten mit schizophrenen Erkrankungen zu beachten: 1. initiales Monitoring zur Identifikation von Patienten mit hohem Risiko für die Entwicklung von Diabetes Typ 2 und kardiovaskulären Erkrankungen; 2. Einleitung einer leitliniengerechten psychopharmakologischen Therapie unter Berücksichtigung individueller Risikofaktoren; 3. kontinuierliches und langfristiges metabolisches Monitoring; 4. präventiver Einsatz von Interventionen zum Gewichtsmanagement und zur Reduktion kardiovaskulärer Risikofaktoren sowie 5. eine gegebenenfalls interdisziplinäre Versorgung schizophrener Patienten.

Summary

The prevalence of the metabolic syndrome is increased in drug-naïve patients with schizophrenia, leading to an increased risk for cardiovascular disorders and diabetes mellitus type 2. Furthermore, treatment of schizophrenia is complicated by the metabolic side effects of common antipsychotic medicaments. Polypharmacy in these patients may also heighten the risk for somatic morbidity. Therefore, the following recommendations should be considered in patients with schizophrenia when treatment is initiated: 1) metabolic monitoring to identify patients at risk for the development of diabetes mellitus type 2 and cardiovascular disorders; 2) start of pharmacological treatment according to treatment guidelines and with regard to the individual metabolic risk factors; 3) continuous monitoring of long duration; 4) implementation of preventive weight management strategies in individual treatment plans to reduce the risk for cardiovascular disorders; 5) if necessary, multidisciplinary treatment of patients with schizophrenia.

Schlüsselwörter

Schizophrenie - Psychopharmaka - metabolisches Syndrom - Diabetes mellitus

Keywords

Schizophrenia - psychotropic drugs - metabolic syndrome - diabetes mellitus
 

  • Literatur

  • 1 Tschoner A, Engl J, Rettenbacher M. et al Effects of six second generation antipsychotics on body weight and metabolism risk assessment and results from a prospective study. Pharmakopsychiatry 2009; 42 (01) 29-34.
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Aronne LJ. et al J Clin Psychiatry. 2003; 62 (Suppl. 08) 22-29.
    PubMedSearch in Google Scholar
  • 3 Himmerich H. et al Gewichtszunahme unter Psychopharmakotherapie. Deutsches Ärzteblatt 2005; 102: A2172-A2177.
    PubMedSearch in Google Scholar
  • 4 Hester EK, Thrower MR. Ann Pharmacotherapy. 2005; 39: 302-310.
    PubMedSearch in Google Scholar
  • 5 Pijl H, Meinders AE. Drug Safety. 1996; 14: 329-342.
    PubMedSearch in Google Scholar
  • 6 Wirshing E. et al J Clin Psychiatry. 1999; 60: 358-363.
    PubMedSearch in Google Scholar
  • 7 Müller JM, Reinehr T, Hebebrand J. Prevention and treatment of child and adolescent obesity-societal as well as behavioural approaches are needed. Deutsches Ärzteblatt 2006; 103 (06) 292-297.
    PubMedSearch in Google Scholar
  • 8 Colditz GA, Willet WC, Rotnitzy A. et al Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122 (07) 481-486.
    CrossrefPubMedSearch in Google Scholar
  • 9 Wilson PW, D’Agostino RB, Levy D. et al Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97 (18) 1837-1847.
    CrossrefPubMedSearch in Google Scholar
  • 10 Thakore J, Leonard BE. Metabolic Effects of Psychotropic Drugs, vol. 26. Basel: Karger; 2009: I-VIII.
    Search in Google Scholar
  • 11 Birkhofer A, Alger P, Schmidt G, Foestl H. The cardivaskulär risk of schizophrenic patients. Neuropsychiatry 2007; 21: 261-266.
    PubMedSearch in Google Scholar
  • 12 Kozaric-Kovacic D, Folnegovic-Smak V, Folnegovic Z, Maruic A. Influence of alcoholism on the prognosis of schizophrenic Patients. J Stud Alcohol 1995; 56: 622-627.
    CrossrefPubMedSearch in Google Scholar
  • 13 Meyer J, Koro CE, L’Italien GJ. The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry 2005; 03: 173-180.
    PubMedSearch in Google Scholar
  • 14 Curkendall SM, Mo J, Glasser DB. et al Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 2004; 65 (05) 715-720.
    CrossrefPubMedSearch in Google Scholar
  • 15 Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M. et al Antipsychotic-induced body weight gain: Predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 2009; 43 (06) 620-626.
    CrossrefPubMedSearch in Google Scholar
  • 16 Allison DB, Mentore JL, Heo M. et al Antipsychoticinduced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156 (11) 1686-1696.
    PubMedSearch in Google Scholar
  • 17 Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004; 05 (Suppl. 01) 7-14.
    PubMedSearch in Google Scholar
  • 18 Drieling T, Biedermann NC, Scharer LO. et al Psychotropic Drug-InducedChange of Weight: A Review. Fortschr Neurol Psychiatr 2007; 75 (02) 65-80.
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Hennekens CH, Hennekens AR, Hollar D. et al Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150 (06) 1115-1121.
    CrossrefPubMedSearch in Google Scholar
  • 20 Mackin P, Young AH. QTc interval measurement and metabolic parametersin psychiatric patients taking typical or atypical antipsychoticdrugs: a preliminary study. J Clin Psychiatry 2005; 66 (11) 1386-1391.
    CrossrefPubMedSearch in Google Scholar
  • 21 Basson BR, Kinon BJ, Taylor CC. et al Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001; 62 (04) 231-238.
    CrossrefPubMedSearch in Google Scholar
  • 22 Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 2006; 29 (04) 303-319.
    CrossrefPubMedSearch in Google Scholar
  • 23 Kinon BJ, Basson BR, Gilmore JA. et al Long-term olanzapine treatment: weight change and weightrelated health factors in schizophrenia. J Clin Psychiatry 2001; 62 (02) 92-100.
    CrossrefPubMedSearch in Google Scholar
  • 24 Ascher-Svanum H, Stensland M, Zhao Z. et al Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2005; 05 (01) 3.
    CrossrefPubMedSearch in Google Scholar
  • 25 Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005; 19 (Suppl. 06) 16-27.
    CrossrefPubMedSearch in Google Scholar
  • 26 Henderson DC, Kunkel L, Nguyen DD. et al An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006; 113 (02) 142-147.
    CrossrefPubMedSearch in Google Scholar
  • 27 Kroeze WK, Hufeisen SJ, Popadak BA. et al H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28 (03) 519-526.
    CrossrefPubMedSearch in Google Scholar
  • 28 Gunes A, Melkersson KI, Scordo MG, Dahl ML. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009; 29 (01) 65-68.
    CrossrefPubMedSearch in Google Scholar
  • 29 Ebenbichler C, Laimer M, KranebitterMet al. The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study. Schizophr Res 2005; 75 (01) 143-146.
    CrossrefPubMedSearch in Google Scholar
  • 30 Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptorpolymorphisms in the pharmacogenetics of antipsychotic drugtreatment. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29 (06) 1021-1028.
    CrossrefPubMedSearch in Google Scholar
  • 31 Leucht S, Corves C, Arbter D. et al Second-generation versus first generation antipsychotic drugs for schizophrenia: am meta-analysis. Lancet 2009; 373 (9657): 4-5.
    CrossrefPubMedSearch in Google Scholar
  • 32 Masopust J, Tuma I, Libiger J. Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment. Neuro Endocrinol Lett 2008; 29 (04) 435-437.
    PubMedSearch in Google Scholar
  • 33 Hauner H, Bender M, Haastert B. et al Plasma concentrations of soluble TNF-alpha receptors in obese subjects. Int J Obes Relat Metab Disord 1998; 22 (12) 1239-1243.
    CrossrefPubMedSearch in Google Scholar
  • 34 Hinze-Selch D, Schuld A, Kraus T. et al Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000; 23 (01) 13-19.
    CrossrefPubMedSearch in Google Scholar
  • 35 Haack M, Hinze-Selch D, Fenzel T. et al Plasma levels of cytokines andsoluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33 (05) 407-418.
    CrossrefPubMedSearch in Google Scholar
  • 36 Jin H, Meyer JM, Mudaliar S, Jeste DV. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 2008; 100 (1-3): 70-85.
    CrossrefPubMedSearch in Google Scholar
  • 37 Reynolds GP. Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 2004; 18 (03) 340-345.
    CrossrefPubMedSearch in Google Scholar
  • 38 Kuzman MR, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 2008; 160 (03) 308-315.
    CrossrefPubMedSearch in Google Scholar
  • 39 Chrousos GP. The role of stress and the hypothalamic-pituitary-adrenalaxis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obes Relat Metab Disord 2000; 24 (Suppl. 02) 50-55.
    PubMedSearch in Google Scholar
  • 40 Cordes J, Klimke A, Kornischka J. et al Therapie der Schizophrenie mit Antipsychotika: Gewichtszunahme ist ein relevanter Faktor. Der Neurologe & Psychiater 2006; 1-2: 45-51.
    PubMedSearch in Google Scholar
  • 41 Cordes J, Sinha-Roeder J, Kahl KG. et al Möglichkeiten des Gewichtsmanagements in der Behandlung schizophrener Psychosen mit atypischen Antipsychotika. Fortschr Neurol Psychiat 2008; 76: 1-12.
    Thieme ConnectPubMedSearch in Google Scholar
  • 42 Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychoticnoncompliance. Schizophr Res 2004; 66 (01) 51-57.
    CrossrefPubMedSearch in Google Scholar
  • 43 Weiden PJ, Daniel DG, Simpson G. et al Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003; 23 (06) 595-600.
    CrossrefPubMedSearch in Google Scholar
  • 44 Kendler KS, Robinette CD. Schizophrenia in the National Academy of Sciences-National Research Council Twin Registry: a 16-year update. Am J Psychiatry 1983; 140: 1551-1563.
    CrossrefPubMedSearch in Google Scholar
  • 45 Mukherjee S, Schur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989; 01: 495.
    PubMedSearch in Google Scholar
  • 46 Van Tilburg J, van Haeften TW, Pearson P, Wijmenga C. Defining the genetic contribution of type 2 diabetes mellitus. J Med Genet 2001; 38: 569-578.
    CrossrefPubMedSearch in Google Scholar
  • 47 Newsome CA, Shiell AW, Fall CH. et al Is birth weight related to later glucose and insulin metabolism? - A systematic review. Diabet Med 2003; 20: 339-348.
    CrossrefPubMedSearch in Google Scholar
  • 48 Jablensky AV, Morgan V, Zubrick SR. et al Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry 2005; 162: 79-91.
    CrossrefPubMedSearch in Google Scholar
  • 49 Katon WJ, Lin EHB, Russo J. et al Cardiac risk factors in patients with diabetes mellitus and major depression. J Gen Intern Med 2004; 19: 1192-1199.
    CrossrefPubMedSearch in Google Scholar
  • 50 McCready RG. Schottish Schizophrenia Lifestyle Group. Diet, smoking, and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003; 183: 534-539.
    CrossrefPubMedSearch in Google Scholar
  • 51 Ziegelstein RC, Fauerbach JA, Stevens SS. et al Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Int Med 2000; 160: 1818-1823.
    CrossrefPubMedSearch in Google Scholar
  • 52 Ryan MCM, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug-naive patients with schizophrenia. Psychoneuroendocrinology 2004; 29: 1065-1070.
    CrossrefPubMedSearch in Google Scholar
  • 53 Kahl KG, Kruse N, Faller H. et al Expression of tumor necrosis factor-α and interferon-γmRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002; 27: 671-681.
    CrossrefPubMedSearch in Google Scholar
  • 54 Kahl KG. Metabolisches Syndrom und psychische Erkrankungen: Relevanz, Risikofaktoren, und praktische Konsequenzen. MMW - Fortschr Med 2005; 147: 32-34.
    PubMedSearch in Google Scholar
  • 55 Maes M. Major depression and activation of the inflammatory response syndrome. Adv Exp Med Biol 1999; 461: 25-46.
    CrossrefPubMedSearch in Google Scholar
  • 56 Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54: 1-78.
    PubMedSearch in Google Scholar
  • 57 Björntorp P. The association between obesity, adipose tissue distribution and disease. Acta Med Scand 1987; 723: 121-134.
    PubMedSearch in Google Scholar
  • 58 Björntorp P. Metabolic implications of fat distribution. Diabetes Care 1991; 14: 1132-1143.
    CrossrefPubMedSearch in Google Scholar
  • 59 Borst SE. The role of TNF- α in insulin resistence. Endocrine 2004; 23: 177-182.
    CrossrefPubMedSearch in Google Scholar
  • 60 Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link beetween insulin resistence, obesity and diabetes. Trends in Immunol 2004; 25: 4-7.
    PubMedSearch in Google Scholar
  • 61 Després J-P, Moorjani S, Lupien PJ. et al Genetic aspects of susceptibility to obesity and related dyslipidemea. Mol Cell Biochem 1992; 113: 151-169.
    PubMedSearch in Google Scholar
  • 62 Ryan MCM, Flanagan S, Kinsella U. et al The effects of atypical antipsychotics an visceral fat distribution in first episode, drug naive patients with schizophrenia. Life Sci 2004; 74: 1999-2008.
    CrossrefPubMedSearch in Google Scholar
  • 63 Thakore JH, Mann JN, Vlahos I. et al Increased visceral fat distribution in drug-naive individuals with and without schizophrenia. Int J Obes Relat Metab Disord 2002; 26: 137-141.
    CrossrefPubMedSearch in Google Scholar
  • 64 Kahl KG, Bester M, Greggersen W. et al Visceral fat deposition and insulin sensitivity in depressed women with and without comorbid borderline personality disorder. Psychosom Med 2005; 67: 407-412.
    CrossrefPubMedSearch in Google Scholar
  • 65 Kroeze WK, Hufeisen SJ, Popadak BA. et al H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28 (03) 519-526.
    CrossrefPubMedSearch in Google Scholar
  • 66 Benkert O, Hippius H. Kompendium der psychiatrischen Pharmakotherapie, 5. Aufl. Heidelberg: Springer; 2005: 161-163.
    Search in Google Scholar
  • 67 American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65 (02) 267-272.
    CrossrefPubMedSearch in Google Scholar